Predicting Treatment Response in Major Depression with the DEX/CRH Test
Author Information
Author(s): Schüle Cornelius, Baghai Thomas C., Eser Daniela, Häfner Sibylle, Born Christoph, Herrmann Sascha, Rupprecht Rainer
Primary Institution: Ludwig-Maximilian-University of Munich
Hypothesis
Can the combined dexamethasone/CRH test predict acute treatment response in major depression?
Conclusion
The DEX/CRH test does not reliably predict therapeutic response, but early attenuation of HPA axis activity may be a better indicator.
Supporting Evidence
- 24.6% of patients were nonsuppressors at admission.
- 39.5% of patients showed enhanced HPA axis function at discharge despite clinical improvement.
- Attenuation of HPA axis activity after 1 week was linked to better treatment outcomes.
Takeaway
Doctors used a test to see if a hormone level could help predict how well patients with depression would respond to treatment, but it didn't work as well as they hoped.
Methodology
The study involved two samples of depressed inpatients undergoing the DEX/CRH test at admission and discharge, with various antidepressant treatments administered.
Potential Biases
Potential biases in patient selection and treatment response assessment.
Limitations
The predictive value of the DEX/CRH test was lower than expected, and early improvement in HPA axis activity was not always followed by a favorable treatment outcome.
Participant Demographics
114 depressed inpatients (53 men, 61 women) aged 18 to 74 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website